TQB2928 not checked
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TQB2928 is a recombinant fully humanized Immunoglobulin G4 (IgG4) monoclonal antibody that can promote tumor cell phagocytosis by macrophages and exert anti-tumor effects. Almonertinib Mesilate Tablets is a third generation of EGFR-TKI targeting drug.”In the company’s words, NCT06585059 on ClinicalTrials.gov
- Tested for
- Advanced Non-small Cell Lung Cancer
- Main trialPhase 1
- “This is a Phase Ib study to evaluate the safety, tolerability, and efficacy of TQB2928 in combination with third-generation EGFR TKIs in subjects with advanced non-small cell lung cancer, and to determine the recommended Phase II dose (RP2CD).”In the company’s words, NCT06585059 on ClinicalTrials.gov
Other drugs for Advanced Non-small Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | Dec 2025 | Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers | |
| Phase 1Unknown | 1 Jul 2022 | Phase 1 Trial of the TQB2928 Injection in Patients With Advanced Cancers | |
| Phase 1Unknown | Jan 2024 | Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers | |
| Phase 1Terminated | 31 Jul 2024 | TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. | |
| Phase 1Unknown | May 2025 | Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy | |
| Phase 1Terminated | 18 Jun 2025 | TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026